CDSCO Approves Innovative Specialty Therapies For Oncology And Metabolic Disorders

In June 2026, the Central Drugs Standard Control Organization granted approval for a series of innovative drugs and specialty therapies. These approvals represent a significant expansion of treatment options available in India, covering diverse therapeutic areas such as oncology, psychiatry, women's health, and metabolic disorders. The move underscores the regulator's commitment to bringing global medical advancements to the domestic market.

Among the notable drugs approved are Izalontamab Brengitecan and Utreglutide (GL0034) solution for injection, which target complex metabolic and oncological conditions. Additionally, the regulator has cleared Surovatamig (AZD0486) and Rilvegostomig (AZD2936), both provided as concentrates for solution for infusion. These therapies are designed to address unmet medical needs, offering new hope for patients suffering from chronic and life-threatening diseases.

The introduction of these specialty therapies is expected to enhance the standard of care across Indian hospitals and clinics. By facilitating the entry of these advanced medical solutions, the CDSCO is actively working to improve patient outcomes in infectious diseases and metabolic health. Healthcare providers are now tasked with integrating these new treatment protocols into their practice, ensuring that patients receive the most current and effective therapeutic interventions available.